Table 1. Patient characteristics .... | American Society of Hematology

Table 1.

Patient characteristics

	Immunophenotype	Cytokine assay	Cytotoxicity assay	Ex vivo activation
HCs
No.	20	12	5	4
Males, %	45	58	60	50
Age, mean (range), y	72 (53-84)	67 (53-79)	68 (62-73)	67 (62-73)
Vγ9Vδ2, mean (range), % of CD3	1.4 (0.1-4.9)	1.5 (0.1-4.9)	1.2 (0.5-1.5)	1.2 (0.5-1.5)
CMV⁺, %	55	50	40	50
CLL patients
No.	39	14	5	8
Males, %	67	50	60	50
Age, mean (range), y	64 (41-87)	67 (55-83)	64 (57-69)	64.9 (57-69)
Vγ9Vδ2, mean (range), % of CD3	1.0 (0.1-6.2)	0.8 (0.1-1.8)	1.3 (0.6-2.6)	1.2 (0.6-2.6)
CMV⁺, %	64.3	50	60	62.5
ALC, mean (range), ×10⁹ cells/L	80.4 (15.3-358.7)	77.4 (19.8-226.1)	51.3 (28.0-95.6)	44.3 (10.6-95.6)
U-CLL, %	43.6	42.9	40	50
Rai stage 0+1, %	72	64	60	62.5

	Immunophenotype	Cytokine assay	Cytotoxicity assay	Ex vivo activation
HCs
No.	20	12	5	4
Males, %	45	58	60	50
Age, mean (range), y	72 (53-84)	67 (53-79)	68 (62-73)	67 (62-73)
Vγ9Vδ2, mean (range), % of CD3	1.4 (0.1-4.9)	1.5 (0.1-4.9)	1.2 (0.5-1.5)	1.2 (0.5-1.5)
CMV⁺, %	55	50	40	50
CLL patients
No.	39	14	5	8
Males, %	67	50	60	50
Age, mean (range), y	64 (41-87)	67 (55-83)	64 (57-69)	64.9 (57-69)
Vγ9Vδ2, mean (range), % of CD3	1.0 (0.1-6.2)	0.8 (0.1-1.8)	1.3 (0.6-2.6)	1.2 (0.6-2.6)
CMV⁺, %	64.3	50	60	62.5
ALC, mean (range), ×10⁹ cells/L	80.4 (15.3-358.7)	77.4 (19.8-226.1)	51.3 (28.0-95.6)	44.3 (10.6-95.6)
U-CLL, %	43.6	42.9	40	50
Rai stage 0+1, %	72	64	60	62.5

ALC, absolute leukocyte count.